DOD taps Valisure to carry out drug quality reviews amid generic shortages, concerns

The De­part­ment of De­fense has se­lect­ed the drug qual­i­ty test­ing com­pa­ny Val­isure to car­ry out qual­i­ty rat­ings for drugs sup­plied to the de­part­ment as law­mak­ers and the FDA are fo­cused on rem­e­dy­ing qual­i­ty con­cerns and re­cent short­ages.

The Val­isure con­tract ful­fills a re­quire­ment of the FY2023 Na­tion­al De­fense Au­tho­riza­tion Act, which di­rect­ed DOD to “as­sess risks to the De­part­ment’s phar­ma­ceu­ti­cal sup­ply chain.” The project aims to re­ward qual­i­ty man­u­fac­tur­ers and pre­vent in­ad­e­quate drugs from reach­ing mil­i­tary ser­vice mem­bers and vet­er­ans, Val­isure said in a press re­lease Tues­day. The FDA is sim­i­lar­ly at­tempt­ing to in­sti­tute qual­i­ty met­rics to fur­ther in­cen­tivize good ac­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.